Trials / Completed
CompletedNCT07362745
Single-Cell and Spatial Transcriptomics Analysis of Steatotic Donor Liver Susceptibility to Post-Transplant Injury
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to understand why liver transplants from donors with fatty liver disease (steatotic donor livers) are more vulnerable to post-transplant injury, analyzing historical clinical data and collected tissue samples using advanced genetic techniques. The main questions it aims to answer are: * Which specific cell types and their spatial interactions contribute to increased post-transplant injury susceptibility in steatotic donor livers? * What are the key molecular differences in gene expression between steatotic and normal donor livers following transplantation? Researchers will compare 300 historical liver transplant cases from 2015-2025, including 50 cases with archived tissue samples available for molecular analysis, and 250 cases with clinical data only. Donor liver steatosis was assessed by histopathology when tissue was available, or by donor clinical data when tissue was not available. The two groups (steatotic donor liver recipients vs. normal donor liver recipients) will be matched based on donor age, ischemia time, recipient scores, and other key clinical parameters to control for potential confounding variables. This is a retrospective analysis of existing data and archived biospecimens; no prospective participant enrollment or additional sample collection will occur.
Conditions
- Fatty Liver
- Liver Transplant; Complications
- Ischaemia Reperfusion Injury of Liver
- End Stage Liver Disease
- Liver Failure
- Postoperative Complications
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2026-01-01
- Completion
- 2026-01-01
- First posted
- 2026-01-23
- Last updated
- 2026-02-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07362745. Inclusion in this directory is not an endorsement.